BV02
Based on 4 publication(s) in Google Scholar
BV02 is a 14-3-3 inhibitor and an antibacterial agent. BV02 enhances the cleavage of PARP and caspase-3. BV02 induces Apoptosis, Autophagy, and enhances Akt activation. BV02 has anti-B. melitensis infection and epilepsy-promoting effects. BV02 can also be used in colitis research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.75%
- CAS No.: 292870-53-2
- Formule: C20H15N3O5
- Masse moléculaire:377.36
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Oxygen Sensing Compound Library
HY-L045
-
Antibacterial Compound Library
HY-L049
-
Glycolysis Compound Library
HY-L058
-
Pyroptosis Compound Library
HY-L059
-
Cytoskeleton Compound Library
HY-L060
-
Glutamine Metabolism Compound Library
HY-L064
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Angiogenesis-Related Compound Library
HY-L088
-
Glucose Metabolism Compound Library
HY-L092
-
Antidepressant Compound Library
HY-L108
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
Lactylation Compound Library
HY-L249
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
Publications Citing Use of MedChemExpress (MCE) BV02
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
|
Caspase-3 |
BV02 (5 μM; 24 h) induces apoptotic death and recruits cells into the sub-G1 phase of the cell cycle in Bcr-Abl-expressing Ba/F3 cells, regardless of whether they express the wild-type Bcr-Abl or the T315I mutation[1].
BV02 (5-50 μM; 24 h) significantly reduces the surface expression of wild-type K2P5.1-GFP channels in HEK293T cells[2].
BV02 (5 μM; 6 h) induces autophagy in C33A cells, with increasing the LC3-II level and decreasing the SQSTM1 level[3].
BV02 (5 μM; 36 h) enhances Akt activation, as shown by increased phosphorylation of Akt at Thr308 and Ser473, and triggers apoptosis in SW480 cells[4].
BV02 (20 μM; 24 h) decreases the invasion of Brucella into macrophages[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SW480 cells
-
Concentration:5 μM
-
Incubation Time:36 h
-
Result:Increased the phosphorylation of Akt at Thr308 and Ser473.
Augmented the cleavage of PARP and caspase-3, indicating apoptosis.
Decreased the level of p-Hist3, a marker of cell proliferation.
BV02 (10 mg/kg; i.p.; 1 day prior to receiving PTZ) weakens the anti-epileptic effects of LV-14-3-3 and LV-HAP1 in Pentylenetetrazole (PTZ)-induced epileptic rats, increasing seizure severity, shortening latency and increasing generalized tonic clonic (GTC) values per rat[5].
BV02 (3 mg/kg; i.p.; once daily; for 3 days starting 10 days post - infection) reduces the splenic load of B. melitensis in infected mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 292870-53-2
-
Appearance Solid
-
Masse moléculaire 377.36
-
Formule C20H15N3O5
-
Color White to off-white
-
SMILES
O=C(C1=CC2=C(C(N(C3=C(C)N(C)N(C4=CC=CC=C4)C3=O)C2=O)=O)C=C1)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Endometrial stromal cell-derived TMAO sustains decidualization to prevent recurrent spontaneous abortion. [Abstract]2026 Feb 3;38(2):316-330.e8. PMID: 41512878 -
Neuro Oncol
A disintegrin and metalloproteinase 22 activates integrin β1 through its disintegrin domain to promote the progression of pituitary adenoma. [Abstract]2024 Jan 5;26(1):137-152. PMID: 37555799 -
bioRxiv
Chronic TGFβ1 Signaling Drives Aberrant Alveolar-Basaloid Metaplasia through a KRT17-Stratifin migratory complex. [Abstract]2026 May 17:2026.05.17.724675. PMID: 42182417 -
Solvant et solubilité
DMSO : 12.5 mg/mL (33.13 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.31 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.31 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (399 KB)
- English - EN (399 KB)
- Français - FR (399 KB)
- Deutsch - DE (399 KB)
- Norwegian - NO (399 KB)
- Español - ES (399 KB)
- Swedish - SV (399 KB)
- Italian - IT (399 KB)
- Korean - KR (399 KB)
- Portuguese - PT (399 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Mancini M, et al. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther. 2011 Mar;336(3):596-604. [Content Brief]
[2]. Fernández-Orth J, et al. 14-3-3 Proteins regulate K2P 5.1 surface expression on T lymphocytes. Traffic. 2017 Jan;18(1):29-43. [Content Brief]
[3]. Kim HJ, et al. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells. Oncotarget. 2017 Jan 24;8(4):6608-6622. [Content Brief]
[4]. Gómez-Suárez M, et al. 14-3-3 Proteins regulate Akt Thr308 phosphorylation in intestinal epithelial cells. Cell Death Differ. 2016 Jun;23(6):1060-72. [Content Brief]
[5]. Wen Y, et al. HAP1 interacts with 14-3-3 to regulate epileptic seizure via GABAAR-mediated inhibitory synaptic transmission in pentylenetetrazole rat model. Neurosci Res. 2022 Sep;182:7-14. [Content Brief]
[6]. Joshi K, et al. Brucella targets the host ubiquitin-specific protease, Usp8, through the effector protein, TcpB, for facilitating infection of macrophages. Infect Immun. 2024 Feb 13;92(2):e0028923. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6500 mL | 13.2501 mL | 26.5002 mL | 66.2504 mL |
| 5 mM | 0.5300 mL | 2.6500 mL | 5.3000 mL | 13.2501 mL | |
| 10 mM | 0.2650 mL | 1.3250 mL | 2.6500 mL | 6.6250 mL | |
| 15 mM | 0.1767 mL | 0.8833 mL | 1.7667 mL | 4.4167 mL | |
| 20 mM | 0.1325 mL | 0.6625 mL | 1.3250 mL | 3.3125 mL | |
| 25 mM | 0.1060 mL | 0.5300 mL | 1.0600 mL | 2.6500 mL | |
| 30 mM | 0.0883 mL | 0.4417 mL | 0.8833 mL | 2.2083 mL |
BV02 Related Classifications
HY-101985 Related Classifications
Powered by Bioz